Topline Phase 2a Data: HT-001 Curbs Itch in Patients on EGFR Inhibitors
Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21, according to positive interim data from the open-label part of Hoth Therapeutics, Inc.’s Phase 2a clinical trial evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.